Agomab Therapeutics NV (AGMB): key financial figures for fiscal year 2025 (in EUR), standardized from XBRL/iXBRL filings by Hub-Equity:
- Net Income/Loss (FY2025)
- -€62.5M
- Total Assets (FY2025)
- €153.7M
- Total Equity (FY2025)
- €130.9M
- Cash Flows from Operating Activities (FY2025)
- -€51.7M
Source: Agomab Therapeutics NV 20-F filing (FY2025). Full income statement, balance sheet and cash flow, restatement-aware and traceable to the source filing, at Hub-Equity.
